Platelet loss during experimental cardiopulmonary bypass and its prevention with prostacyclin

J. R. Plachetka, N. W. Salomon, Douglas F Larson, J. G. Copeland

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Prostacyclin (PGI2), a newly discovered short-acting prostaglandin that inhibits platelet aggregation, was evaluated as an agent for prevention of cardiopulmonary bypass-induced thrombocytopenia. Ten adult, splenectomized greyhounds were divided into 3 treatment groups prior to beginning 120 minutes of partial cardiopulmonary bypass. Group 1 animals received 300 units of heparin per kilogram of body weight, Group 2 animals received 300 units of heparin per kilogram plus PGI2, 1.5 μg per minute, and Group 3 animals received 300 units of heparin per kilogram plus PGI2 3.0 μg per minute. Bypass and PGI2 infusion were started simultaneously. Mean platelet counts of each group at 5 minutes were approximately 40% of prebypass levels. Additional platelet loss was seen in Groups 1 and 2 at 30, 60, and 120 minutes. However in Group 3, platelet counts at 30 and 60 min. were essentially unchanged from prebypass levels. At 30, 60, and 120 minutes of cardiopulmonary bypass, the differences between Groups 1 and 3, and 2 and 3 are highly significant (p<0.01). We conclude that PGI2 is an effective agent for preserving platelet levels during experimental cardiopulmonary bypass. Furthermore, it is possible that platelet loss during cardiopulmonary bypass may be caused, in part, by an imbalance between PGI2 and thromboxane A2, which results in excessive platelet adhesion and aggregation.

Original languageEnglish (US)
Pages (from-to)58-63
Number of pages6
JournalAnnals of Thoracic Surgery
Volume30
Issue number1
StatePublished - 1980

Fingerprint

Epoprostenol
Cardiopulmonary Bypass
Blood Platelets
Heparin
Platelet Count
Platelet Aggregation
Thromboxane A2
Thrombocytopenia
Prostaglandins
Body Weight

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Platelet loss during experimental cardiopulmonary bypass and its prevention with prostacyclin. / Plachetka, J. R.; Salomon, N. W.; Larson, Douglas F; Copeland, J. G.

In: Annals of Thoracic Surgery, Vol. 30, No. 1, 1980, p. 58-63.

Research output: Contribution to journalArticle

Plachetka, J. R. ; Salomon, N. W. ; Larson, Douglas F ; Copeland, J. G. / Platelet loss during experimental cardiopulmonary bypass and its prevention with prostacyclin. In: Annals of Thoracic Surgery. 1980 ; Vol. 30, No. 1. pp. 58-63.
@article{2798f3a5ff1d4fc9b9acf03589fd9b43,
title = "Platelet loss during experimental cardiopulmonary bypass and its prevention with prostacyclin",
abstract = "Prostacyclin (PGI2), a newly discovered short-acting prostaglandin that inhibits platelet aggregation, was evaluated as an agent for prevention of cardiopulmonary bypass-induced thrombocytopenia. Ten adult, splenectomized greyhounds were divided into 3 treatment groups prior to beginning 120 minutes of partial cardiopulmonary bypass. Group 1 animals received 300 units of heparin per kilogram of body weight, Group 2 animals received 300 units of heparin per kilogram plus PGI2, 1.5 μg per minute, and Group 3 animals received 300 units of heparin per kilogram plus PGI2 3.0 μg per minute. Bypass and PGI2 infusion were started simultaneously. Mean platelet counts of each group at 5 minutes were approximately 40{\%} of prebypass levels. Additional platelet loss was seen in Groups 1 and 2 at 30, 60, and 120 minutes. However in Group 3, platelet counts at 30 and 60 min. were essentially unchanged from prebypass levels. At 30, 60, and 120 minutes of cardiopulmonary bypass, the differences between Groups 1 and 3, and 2 and 3 are highly significant (p<0.01). We conclude that PGI2 is an effective agent for preserving platelet levels during experimental cardiopulmonary bypass. Furthermore, it is possible that platelet loss during cardiopulmonary bypass may be caused, in part, by an imbalance between PGI2 and thromboxane A2, which results in excessive platelet adhesion and aggregation.",
author = "Plachetka, {J. R.} and Salomon, {N. W.} and Larson, {Douglas F} and Copeland, {J. G.}",
year = "1980",
language = "English (US)",
volume = "30",
pages = "58--63",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Platelet loss during experimental cardiopulmonary bypass and its prevention with prostacyclin

AU - Plachetka, J. R.

AU - Salomon, N. W.

AU - Larson, Douglas F

AU - Copeland, J. G.

PY - 1980

Y1 - 1980

N2 - Prostacyclin (PGI2), a newly discovered short-acting prostaglandin that inhibits platelet aggregation, was evaluated as an agent for prevention of cardiopulmonary bypass-induced thrombocytopenia. Ten adult, splenectomized greyhounds were divided into 3 treatment groups prior to beginning 120 minutes of partial cardiopulmonary bypass. Group 1 animals received 300 units of heparin per kilogram of body weight, Group 2 animals received 300 units of heparin per kilogram plus PGI2, 1.5 μg per minute, and Group 3 animals received 300 units of heparin per kilogram plus PGI2 3.0 μg per minute. Bypass and PGI2 infusion were started simultaneously. Mean platelet counts of each group at 5 minutes were approximately 40% of prebypass levels. Additional platelet loss was seen in Groups 1 and 2 at 30, 60, and 120 minutes. However in Group 3, platelet counts at 30 and 60 min. were essentially unchanged from prebypass levels. At 30, 60, and 120 minutes of cardiopulmonary bypass, the differences between Groups 1 and 3, and 2 and 3 are highly significant (p<0.01). We conclude that PGI2 is an effective agent for preserving platelet levels during experimental cardiopulmonary bypass. Furthermore, it is possible that platelet loss during cardiopulmonary bypass may be caused, in part, by an imbalance between PGI2 and thromboxane A2, which results in excessive platelet adhesion and aggregation.

AB - Prostacyclin (PGI2), a newly discovered short-acting prostaglandin that inhibits platelet aggregation, was evaluated as an agent for prevention of cardiopulmonary bypass-induced thrombocytopenia. Ten adult, splenectomized greyhounds were divided into 3 treatment groups prior to beginning 120 minutes of partial cardiopulmonary bypass. Group 1 animals received 300 units of heparin per kilogram of body weight, Group 2 animals received 300 units of heparin per kilogram plus PGI2, 1.5 μg per minute, and Group 3 animals received 300 units of heparin per kilogram plus PGI2 3.0 μg per minute. Bypass and PGI2 infusion were started simultaneously. Mean platelet counts of each group at 5 minutes were approximately 40% of prebypass levels. Additional platelet loss was seen in Groups 1 and 2 at 30, 60, and 120 minutes. However in Group 3, platelet counts at 30 and 60 min. were essentially unchanged from prebypass levels. At 30, 60, and 120 minutes of cardiopulmonary bypass, the differences between Groups 1 and 3, and 2 and 3 are highly significant (p<0.01). We conclude that PGI2 is an effective agent for preserving platelet levels during experimental cardiopulmonary bypass. Furthermore, it is possible that platelet loss during cardiopulmonary bypass may be caused, in part, by an imbalance between PGI2 and thromboxane A2, which results in excessive platelet adhesion and aggregation.

UR - http://www.scopus.com/inward/record.url?scp=0018832761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018832761&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 58

EP - 63

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 1

ER -